All Resolutions Passed at SCHOTT Pharma's AGM

SCHOTT Pharma AG & Co. KGaA successfully held its Annual General Meeting on February 3, 2026, for the fiscal year 2025. During the meeting, shareholders approved all proposed resolutions, which included discharging the Board of Management and the Supervisory Board. Notably, a dividend of EUR 0.18 per share was sanctioned, representing 18% of the consolidated net income. A significant accomplishment was the representation of over 95% of the share capital during the meeting. This approval reflects strong shareholder support.

SCHOTT Pharma is renowned for its drug containment solutions and delivery systems. The company caters to over 1,800 customers, including top pharma manufacturers, and achieved revenue of EUR 986 million in 2025. Headquartered in Mainz, Germany, and listed on the SDAX, SCHOTT Pharma is committed to innovation and sustainability.